Fate Therapeutics
FATE
122 hedge funds and large institutions have $762M invested in Fate Therapeutics in 2018 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 52 increasing their positions, 33 reducing their positions, and 19 closing their positions.
58% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 33
32% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 19
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
5% more funds holding
Funds holding: 116 → 122 (+6)
4.84% more ownership
Funds ownership: 87.27% → 92.1% (+4.8%)
6% more call options, than puts
Call options by funds: $2.57M | Put options by funds: $2.43M
15% less capital invested
Capital invested by funds: $893M → $762M (-$131M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$23.3M |
| 2 |
BlackRock
New York
|
+$21.8M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
+$11M |
| 4 |
DM
Deerfield Management
New York
|
+$6.71M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$6.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$29.5M |
| 2 |
PVMCV
Polaris Venture Management Co V
Boston,
Massachusetts
|
-$9.06M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$7.19M |
| 4 |
ACM
Aquilo Capital Management
San Francisco,
California
|
-$4.01M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.58M |
FATE Hedge Fund Activity: Q4 2018 in Review
122 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q4 2018, worth a combined $762M — down 15% from $893M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new FATE positions and 19 closed out — a net gain of 6 holders — while 52 added to existing stakes and 33 trimmed.
The largest buyer was Farallon Capital Management, adding an estimated $23.3M. The largest seller was Franklin Resources, cutting an estimated $29.5M.
- 122 institutional investors held Fate Therapeutics (FATE) as of Q4 2018, up from 116 in Q3 2018.
- Funds reported $762M of Fate Therapeutics stock for Q4 2018, down 15% quarter-over-quarter.
- 25 funds opened new Fate Therapeutics positions in Q4 2018 and 19 closed out, a net change of +6 holders.
- The largest Fate Therapeutics buyer in Q4 2018 was Farallon Capital Management, an estimated $23.3M added.
- The largest Fate Therapeutics seller in Q4 2018 was Franklin Resources, an estimated $29.5M sold.
Based on aggregated 13F filings for Q4 2018.